Chief Financial OfficerCIK 0001817217
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 11 | van Houte HansChief Financial Officer |  NRIXNurix Therapeutics, Inc.Open-market sale · 10b5-1 plan | SELL | $24K 1,469 sh | Nov 4, 2026 traded Nov 4, 2026 | |
van Houte HansChief Financial Officer |
| NRIXNurix Therapeutics, Inc. Open-market sale · 10b5-1 plan |
| SELL |
| $51K 3,300 sh |
| Nov 4, 2026 traded Nov 4, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,573 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 34 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $74K 2,834 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 17 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Nov 2, 2026 traded Oct 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 27 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $40K 2,388 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 5 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,858 sh | Apr 30, 2026 traded Apr 30, 2026 |
| 17 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,887 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 3,750 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 13 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,859 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 38 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $59K 3,588 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 31 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Open-market sale | SELL | $1,268 73 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,887 sh | Jan 30, 2026 traded Jan 30, 2026 |
| 9 | van Houte HansChief Financial Officer | NRIXNurix Therapeutics, Inc. Option exercise | M | — 2,000 sh | Jan 30, 2026 traded Jan 30, 2026 |